MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKKGY) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 24,500 shares, a growth of 665.6% from the September 15th total of 3,200 shares. Based on an average daily volume of 74,300 shares, the days-to-cover ratio is currently 0.3 days.
Several equities analysts have issued reports on MKKGY shares. Morgan Stanley reaffirmed an “equal weight” rating on shares of MERCK Kommanditgesellschaft auf Aktien in a report on Friday, September 17th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of MERCK Kommanditgesellschaft auf Aktien in a report on Monday, September 13th. UBS Group lowered shares of MERCK Kommanditgesellschaft auf Aktien from a “neutral” rating to a “sell” rating in a report on Tuesday, September 14th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of MERCK Kommanditgesellschaft auf Aktien in a report on Friday, September 10th. Finally, Societe Generale reaffirmed a “hold” rating on shares of MERCK Kommanditgesellschaft auf Aktien in a report on Friday, August 6th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold”.
Shares of MKKGY traded up $1.15 during midday trading on Thursday, reaching $44.51. The stock had a trading volume of 22,557 shares, compared to its average volume of 50,303. The company’s fifty day simple moving average is $45.84 and its two-hundred day simple moving average is $39.98. MERCK Kommanditgesellschaft auf Aktien has a 1-year low of $28.87 and a 1-year high of $49.08.
Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility.
Read More: Equity Income
Receive News & Ratings for MERCK Kommanditgesellschaft auf Aktien Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MERCK Kommanditgesellschaft auf Aktien and related companies with MarketBeat.com's FREE daily email newsletter.